Drug Profile
Muparfostat
Alternative Names: Mannopentaose phosphate sulfate; Muparfostat sodium; Phosphomannopentaose sulfate; PI-88; PI-88 sodium; PI88-cpd; Sulfated mannopentaose phosphateLatest Information Update: 05 Jul 2022
Price :
$50
*
At a glance
- Originator Australian National University
- Developer Medigen Biotechnology Corporation; Progen Pharmaceuticals; Progen Pharmaceuticals Limited; TBG Diagnostics Limited
- Class Antineoplastics; Antithrombotics; Mannans; Oligosaccharides
- Mechanism of Action Fibroblast growth factor inhibitors; Heparanase inhibitors; Heparin cofactor II stimulants; Lipoprotein-associated coagulation inhibitor stimulants; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Liver cancer
- Phase I/II Solid tumours
- Discontinued Cardiovascular disorders; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Thrombosis
Most Recent Events
- 23 Jun 2022 Cellxpert Biotechnology completes a phase II trial in Liver cancer in Taiwan (NCT00247728)
- 09 Aug 2017 Adverse events and efficacy data from the phase III PATRON trial in Liver cancer released by Medigen Biotechnology
- 08 Aug 2017 Adverse events data from a phase II trial in Liver cancer released by Medigen Biotechnology